Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30705737 | 1.00 | DRD3 (0.50) | DRD3RAB9ARORCDRD2PSEN1 | |
| SCHEMBL8688537 | 0.90 | DRD3 (0.50) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL8689595 | 0.89 | DRD3 (0.46) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL8691516 | 0.87 | DRD3 (0.46) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL30705735 | 0.87 | DRD3 (0.46) | DRD3DRD2DRD4HTR1DHTR1B | |
| Cyclopropane Carboxylic Acid SCHEMBL17822673 | 0.87 | TAS2R14 (0.48) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL8689579 | 0.82 | DRD3 (0.48) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL30705739 | 0.82 | DRD3 (0.48) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL7451185 | 0.79 | DRD3 (0.55) | DRD3DRD2DRD4HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL7448937 | 0.78 | DRD3 (0.54) | DRD3DRD2DRD4HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288541-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2025-09-18 | — | — | US | disclosed |
| US-12357590-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-12350242-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2025-07-08 | — | — | US | disclosed |
| US-12064402-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2024-08-20 | — | — | US | disclosed |
| WO-2024062395-A1 | USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME | Clearmind Medicine Inc. (IL) | 2024-03-28 | — | — | WO | disclosed |
| CN-112500301-B | Regulator for longitudinal behavior | 以西结·戈兰 | 2024-02-13 | — | — | CN | disclosed |
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | Clearmind Medicine Inc. (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11528924-B2 | Alcoholic beverage substitutes | Clearmind Medicine, Inc. (CA) | 2022-12-20 | — | — | US | disclosed |
| CN-114903134-A | Alcoholic beverage substitute | 以西结·戈兰 | 2022-08-16 | — | — | CN | disclosed |
| CN-114403335-A | Alcoholic beverage substitute | 以西结·戈兰 | 2022-04-29 | — | — | CN | disclosed |
| US-20190054042-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2019-02-21 | — | — | US | disclosed |
| US-10137096-B2 | Binge behavior regulators | CLEARMIND LABS CORP. (CA) | 2018-11-27 | — | — | US | disclosed |
| US-20180085326-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2018-03-29 | — | — | US | disclosed |
| US-20170360067-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | CLEARMIND LABS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| EP-3230255-A1 | BINGE BEHAVIOR REGULATORS | Golan, Ezekiel (CA) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230256-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | Golan, Ezekiel (CA) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092547-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092546-A1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| EP-0712387-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004713-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | THE UPJOHN COMPANY (US) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288541-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | DRD3 131/4885RAB9A 2239/4885RORC 3665/4885 |
| US-20180085326-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | DRD3 131/4885RAB9A 2239/4885RORC 3665/4885 |
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | ADH1A, ADH5, ADH1C | DRD3 431/4885RAB9A 4348/4885RORC 2386/4885 |
| US-12350242-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD3 131/4885RAB9A 2239/4885RORC 3665/4885 |
| US-10137096-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD3 131/4885RAB9A 2239/4885RORC 3665/4885 |
| US-12064402-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD3 131/4885RAB9A 2239/4885RORC 3665/4885 |
| US-20190054042-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | DRD3 131/4885RAB9A 2239/4885RORC 3665/4885 |
| US-11528924-B2 | Alcoholic beverage substitutes | ADH1A, ADH5, ADH1C | DRD3 431/4885RAB9A 4348/4885RORC 2386/4885 |
| US-12357590-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD3 131/4885RAB9A 2239/4885RORC 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.